These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8200723)

  • 1. Pharmacokinetics and electroencephalographic effects of darodipine 50-200 mg modified release (MR) acute oral administration: dose-finding study in healthy volunteers.
    Sannita WG; Busico S; Di Bon G; Ferrari A; Riela S
    Int J Clin Pharmacol Res; 1993; 13(5):281-91. PubMed ID: 8200723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentration and CNS effects of Ca antagonists darodipine and nimodipine after single-dose oral administration to healthy volunteers.
    Sannita WG; Garbarino S; Gesino D; Massimilla S; Ogliastro C
    Neuropsychobiology; 1999 Sep; 40(3):158-70. PubMed ID: 10494052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration.
    Saletu B; Grünberger J; Anderer P; Linzmayer L; König P
    Arzneimittelforschung; 1995 Mar; 45(3):217-29. PubMed ID: 7741773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.
    Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.
    Cheung WK; Woodward DL; Shin K; Hibberd M; Pearse S; Desjardins RE; Yacobi A; Silber BM
    Int J Clin Pharmacol Res; 1988; 8(5):299-305. PubMed ID: 3229870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
    Cainazzo MM; Pinetti D; Savino G; Bartiromo M; Forgione A; Bertolini A
    Drugs Exp Clin Res; 2005; 31(3):115-21. PubMed ID: 16033250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers.
    Ragueneau I; Sao AB; Démolis JL; Darné B; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 2001 Mar; 69(3):122-9. PubMed ID: 11240976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses.
    Tröger U; Martens J; Meyer FP; Hoffmann A; Terhaag B
    Arzneimittelforschung; 1995 Dec; 45(12):1266-70. PubMed ID: 8595082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets].
    Vidal-Gárate J; Castañeda Hernández G; Hoyo Vadillo C; Herrera Abarca JE; Salazar LA; Moreno Ramos A; Fortino Chávez J; Tena I; Hong E
    Arch Inst Cardiol Mex; 1989; 59(1):73-80. PubMed ID: 2486739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation.
    Saletu B; Barbanoj MJ; Anderer P; Sieghart W; Grünberger J
    Methods Find Exp Clin Pharmacol; 1993 Jun; 15(5):291-312. PubMed ID: 8412414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration.
    Castañeda-Hernández G; Hoyo-Vadillo C; Herrera JE
    Int J Clin Pharmacol Ther; 1995 Jan; 33(1):56-60. PubMed ID: 7711994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of nifedipine controlled release on blood pressure and heart rate of spontaneously hypertensive rats. Comparison with nifedipine standard and with amlodipine].
    Di Filippo C; Lampa E; Forgione A; Capuano A; Rossi F; D'Amico M
    Ital Heart J Suppl; 2005 May; 6(5):285-90. PubMed ID: 15934425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo.
    Greenblatt DJ; Legangneux E; Harmatz JS; Weinling E; Freeman J; Rice K; Zammit GK
    J Clin Pharmacol; 2006 Dec; 46(12):1469-80. PubMed ID: 17101746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.